Overview

A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, prospective open-label study to assess the efficacy and safety of combination of peginterferon alfa-2b (40kD, Y-shape) and GM-CSF in interferon-naïve chronic hepatitis B patients with HBeAg positive. Patients were randomized to one of the 2 groups to receive different antiviral treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Xiamen Amoytop Biotech Co., Ltd.
Collaborator:
Peking University First Hospital
Treatments:
Interferon-alpha
Molgramostim
Peginterferon alfa-2b
Sargramostim